胰高血糖素样肽1受体激动剂与口服药物相互作用系统综述
结果显示GLP1RA可降低Cmax并延迟tmax,但AUC无临床显著变化,通常无需调整剂量,但肾功能不全或窄治疗指数药物需谨慎。
要点
- GLP1RA可降低口服药物Cmax并延迟tmax,与胃排空延迟一致。
- 总体AUC无临床显著变化,通常无需调整口服药物剂量。
- 肾功能不全或使用窄治疗指数药物时需谨慎解读。
核心结论
- GLP1RA与口服药物联用时Cmax降低和tmax延迟与胃排空延迟一致,但总体药物暴露无临床显著变化。
- 同时使用GLP1RA与口服药物可能无需剂量调整,但肾功能不全或窄治疗指数药物需谨慎。
研究设计与样本
- 纳入任何注射用GLP1RA与口服药物合用的药代动力学研究。
主要发现
- 高溶解高渗透性药物(华法林、避孕药、对乙酰氨基酚)、高溶解低渗透性药物(ACEI)、低溶解高渗透性药物(他汀类)和低溶解低渗透性药物(地高辛)的Cmax未受影响或降低,tmax延迟。
- GLP1RA使用未导致AUC的临床显著变化或临床相关终点的差异。
临床怎么用
- 同时使用GLP1RA与口服药物时通常无需调整剂量。
- 肾功能不全或使用窄治疗指数药物时需谨慎,并密切监测。
局限性
- 纳入研究主要入选健康受试者,肾功能不全等影响药代动力学的情况数据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP1RAs) are used in the treatment of diabetes and obesity. Their slowing effect of gastric emptying might change oral drug absorption, potentially affecting pharmacokinetics, particularly in the case of medications with a narrow therapeutic index. PURPOSE: The purpose of this systematic review is to summarize data on drug-drug interactions between GLP1RAs and oral drugs. DATA SOURCES: The PubMed and EMBASE databases were searched up to November, 1st 2023. STUDY SELECTION: We selected pharmacokinetic studies of any injectable GLP1RA given with an oral medication, and product prescribing sheets reporting data without access to the original study. DATA EXTRACTION: Two authors independently extracted the data. DATA SYNTHESIS: Twenty-two reports and six prescribing sheets were included. Treatment with GLP1RAs resulted in unaffected or reduced Cmax and delayed tmax of drugs with high solubility and permeability (warfarin, contraceptive pills, acetaminophen), drugs with high solubility and low permeability (angiotensin converting enzyme inhibitors), drugs with low solubility and high permeability (statins) and drugs with low solubility and permeability (digoxin). However, the use of GLP1RAs did not exert clinically significant changes in the AUC or differences in clinically relevant endpoints. LIMITATIONS: The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction). CONCLUSIONS: To conclude, reduced Cmax and delayed tmax of drugs co-administered with GLP1RAs are consistent with the known delayed gastric output by the latter. Nevertheless, the overall drug exposure was not considered clinically significant. Dose adjustments are probably not required for simultaneous use of GLP1RAs with oral medications. Still, results should be carefully generalized to cases of background kidney dysfunction or when using drugs with narrow therapeutic index. The study is registered in PROSPERO: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022332339 .
引用
- Calvarysky B, Dotan I, Shepshelovich D, et al. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024. PMID: 38273155. doi:10.1007/s40264-023-01392-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。